Alza Corporation

Intarcia Therapeutics, Inc.

Other

John R. Peery

James B. Eckenhoff

Jeremy C. Wright

Frederick H. Maruyama

James B Eckenhoff

John R Peery

Jeremy C Wright

Richard Lewis Cortese

Judy A Magruder

Felix A Landrau

Felix T Theeuwes

Patrick S Wong

Keith E Dionne

Scott D Lautenbach

Joseph C Deters

Steven D Larsen

John P Carr

Hoa T Huynh

Virgil A Place

Frederick H Maruyama

David L Rivera

Terry L Burkoth

Patricia S Campbell

James L Osborne

Sonya Merrill

Atul D Ayer

Anthony L Kuczynski

James B Pike

Jonathan P Smith

Urano A Robinson

Lyle Elmore Ziemann

John R Perry

Bonnie J Eckenhoff, Legal Representative

Su Il Yum

John Urquhart

Johan H Geerke

Rupal A Ayer

Cynthia L Stevenson

Stephen A Berry

Steven J Prestrelski

Sally A Tao

John J Leonard, Jr

Fred H Maruyama

Scott D Jordan

Neil Arthur Johnson

Gregory R Stewart

Kevin J Mullins

The invention is directed to a device for delivering an active agent formulation for a predetermined administration period. An impermeable reservoir is divided into a water-swellable agent chamber and an active agent formulation chamber. Fluid from the environment is imbibed through a semipermeable plug into the water-swellable agent chamber and the active agent formulation is released through a back-diffusion regulating outlet. Delivery periods of up to 2 years are achieved.

Sustained delivery of an active agent using an implantable system

An osmotic delivery system for controlled delivery of a beneficial agent includes an implant capsule having a beneficial agent reservoir, an osmotic agent which expands on contact with fluid imbibed through a permeable membrane retained by the implant capsule, a delivery port, and a valve for opening and closing the delivery port. When the osmotic agent expands, a pressure is exerted against a separating member positioned between the beneficial agent reservoir and the osmotic agent. The separating member moves within the capsule, thereby forcing the valve to move a distance such that the beneficial agent can exit the reservoir through the delivery port.

Valve for osmotic devices

Performance of delivery systems for delivering beneficial agents to an animal are monitored to determine the delivery rate of the beneficial agent and the proper operation of the beneficial agent delivery device. Performance monitoring can be achieved by monitoring the physical configuration of the implanted osmotic delivery device from the exterior of the body to determine the amount of beneficial agent delivered and/or the delivery rate of the beneficial agent. The monitoring of the physical configuration of the implanted osmotic delivery device may be performed in different manners such as by X-ray or fluoroscopic monitoring of the implant structure or magnetic determination of a piston location within the implant. Performance monitoring can also be achieved by use of a performance marker within the beneficial agent to produce a specifically detectable response which can be measured noninvasively in body fluids or by-products.

Osmotic drug delivery monitoring system and method

A delivery system is disclosed for delivering a beneficial agent to an animal. The delivery system comprises a wall that surrounds a lumen, said wall comprising a composition that limits the passage of fluid into the system and a composition that permits the passage of fluid into the system. The lumen comprises a beneficial agent and an expandable member. The delivery system comprises an exit means for delivering the beneficial agent.

Polyurethane-containing delivery systems

This invention relates to stable non-aqueous protic formulations of peptide compounds. These stable formulations comprise peptide in non-aqueous protic solvent. They may be stored at elevated temperatures for long periods of time and are especially useful in implantable delivery devices for long term delivery of drug.

Non-aqueous protic peptide formulations

A delivery system is disclosed for delivering a fluid-sensitive beneficial agent such as a somatotropin, or an analogue or derivative thereof, to an animal such as a bovine. The delivery system comprises a wall that surrounds an internal compartment, said wall comprising a first wall section that limits the passage of fluid into the system and a second wall section that permits the passage of fluid into the system. The wall may further comprise an end cap which may be adapted for ultrasonic welding to the first wall section and may maintain the beneficial agent in contact with an exit. The compartment comprises a beneficial agent and an expandable driving member. The delivery system comprises an exit for delivering the beneficial agent to the animal. The exit may compensate for slight variations in the efflux rate of the beneficial agent and maintain a sufficient velocity or efflux rate of beneficial agent outward from the device while minimizing diffusion of fluids from the external environment back into the device.

Osmotic system for delivery of fluid-sensitive somatotropins to bovine

A dispenser for use in a fluid environment of use which is capable of the delivery of one or a plurality of discrete active agent-containing units in any desired delivery pattern or profile. It also can provide for the initially delayed delivery of an active agent to the environment of use and for high accuracy in the timing of delivery of the active agent.

Osmotic device for delayed delivery of agent

Growing community of inventors

Los Altos, CA, United States of America

James B Eckenhoff